- within Food, Drugs, Healthcare and Life Sciences topic(s)
- within Consumer Protection, Tax and International Law topic(s)
Nigeria's health and pharmaceutical sector closed Q1 2026 at a critical turning point, with the quarter marked by notable clinical milestones that signal bigger structural change across the industry, including the introduction of West Africa's first robotic-assisted gynaecological surgery.
On the policy front, the Federal Government activated Medipool as a national bulk procurement mechanism targeting medicine cost reductions of between 20 and 30 per cent, whilst President Tinubu transmitted 24 health sector reform bills to the Senate. Lagos and Kano States, amongst others, advanced mandatory health insurance schemes, and the Nigeria Sovereign Investment Authority moved to expand specialist healthcare infrastructure through the Medserve initiative. NAFDAC, for its part, maintained an unusually high tempo of enforcement activity, issuing alerts on counterfeit cancer medicines, contraceptives, and other products, whilst the Federal Government extended its regulatory reach into the cosmetics industry.
The quarter's most consequential unresolved matter is the legal challenge to the Nigeria–US Bilateral Health Cooperation MOU, which, if upheld, could disrupt approximately $2.1 billion in US health commitments over five years. Q2 2026 will test whether the considerable policy architecture assembled in Q1 can withstand legal and operational scrutiny and be translated into measurable reform.
Open PDF to continue reading >>
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
